Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Combination Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

NCT06767956 is registered in ClinicalTrials.gov with University of Pittsburgh as lead sponsor.

NCT NCT06767956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06767956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Combination Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
Lead sponsor
University of Pittsburgh
Phase
Phase 1/2
Overall status
Withdrawn
Start date
June 30, 2025
Completion date
April 30, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non hodgkin lymphoma